Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,030 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L. Raghu G, et al. Among authors: hamblin mj. JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129. JAMA. 2018. PMID: 29800034 Free PMC article. Clinical Trial.
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L. Raghu G, et al. Among authors: hamblin mj. Lancet Respir Med. 2019 Aug;7(8):657-664. doi: 10.1016/S2213-2600(19)30172-9. Epub 2019 May 20. Lancet Respir Med. 2019. PMID: 31122893 Clinical Trial.
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.
Raghu G, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Raghu G, et al. Among authors: hamblin mj. Respir Res. 2022 May 21;23(1):129. doi: 10.1186/s12931-022-02047-0. Respir Res. 2022. PMID: 35597980 Free PMC article. Clinical Trial.
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.
Adegunsoye A, Oldham JM, Fernández Pérez ER, Hamblin M, Patel N, Tener M, Bhanot D, Robinson L, Bullick S, Chen L, Hsu S, Churpek M, Hedeker D, Montner S, Chung JH, Husain AN, Noth I, Strek ME, Vij R. Adegunsoye A, et al. Among authors: hamblin m. ERJ Open Res. 2017 Aug 17;3(3):00016-2017. doi: 10.1183/23120541.00016-2017. eCollection 2017 Jul. ERJ Open Res. 2017. PMID: 28845429 Free PMC article.
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I; CleanUP-IPF Investigators of the Pulmonary Trials Cooperative. Martinez FJ, et al. JAMA. 2021 May 11;325(18):1841-1851. doi: 10.1001/jama.2021.4956. JAMA. 2021. PMID: 33974018 Free PMC article. Clinical Trial.
1,030 results